Estamos cerca de ese 5’99 que de perforar abriría la caja de Pandora y todos sus horribles bichejos.

Los aparatejos empiezan a pedir socorro y la necesidad de un rebote, pero………¡FÍJATE!, ME GUSTARÍA QUE LO TANTEARA HOY MISMO Y SE DEJARA DE HISTORIAS Y MONEOS VARIOS.

«Represents a key cornerstone of AMRN’s long term strategy to eke out a solid market position in the cardio space. We reiterate buy and $35 target.

Contrary to claims that the sole advantage of a fixed dose combo product would be convenience we would point out that combo agents are popular in the cardio space and that they are designed to provide additional long term benefit beyond that achievable with single agents alone.

FDA panel does not present cause for concern…both ANCHOR and REDUCE-IT are subject of SPA.

Also contrary to what some have stated, that there is no outcomes data in mixed dyslipidemia for V, there is substantial cardiac outcomes based evidence most notably from the JELIS trial conducted in Japan..

Various catalysts approaching.

We believe AMRN remains highly likely to receive NCE status for V.

AMRN also expects to complete enrollment in the REDUCE-IT cardiac outcomes study soon, we believe full enrollment could be reached early n 2014. Roughly 4,500 patients to date .

http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=772903

buenas cifras